Swiss National Bank held its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 113,700 shares of the biopharmaceutical company’s stock at the end of the first quarter. Swiss National Bank owned about 0.15% of Inovio Pharmaceuticals worth $753,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of INO. Bank of New York Mellon Corp boosted its stake in shares of Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after buying an additional 11,765 shares during the period. Stoneridge Investment Partners LLC boosted its stake in shares of Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock worth $1,684,000 after buying an additional 2,073 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Inovio Pharmaceuticals by 28.9% in the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock worth $825,000 after buying an additional 27,898 shares during the period. Vident Investment Advisory LLC boosted its stake in shares of Inovio Pharmaceuticals by 67.5% in the fourth quarter. Vident Investment Advisory LLC now owns 106,147 shares of the biopharmaceutical company’s stock worth $737,000 after buying an additional 42,764 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth $559,000. Institutional investors and hedge funds own 22.92% of the company’s stock.

Shares of Inovio Pharmaceuticals, Inc. (INO) traded down 3.72% on Tuesday, hitting $5.43. The stock had a trading volume of 1,356,381 shares. The company’s market cap is $405.22 million. Inovio Pharmaceuticals, Inc. has a 12-month low of $5.32 and a 12-month high of $9.95. The stock has a 50 day moving average price of $7.16 and a 200-day moving average price of $6.84.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). The company had revenue of $10.40 million during the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The company’s revenue was up 28.4% on a year-over-year basis. During the same period last year, the firm earned ($0.11) earnings per share. On average, equities analysts expect that Inovio Pharmaceuticals, Inc. will post ($1.07) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/08/swiss-national-bank-has-753000-position-in-inovio-pharmaceuticals-inc-nasdaqino-updated-updated-updated.html.

INO has been the subject of a number of analyst reports. Aegis restated a “buy” rating and set a $14.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, July 18th. Maxim Group increased their price target on Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. ValuEngine upgraded Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a research note on Tuesday, April 25th. Finally, Zacks Investment Research cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 17th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Inovio Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $20.78.

In other news, Director David B. Weiner sold 8,000 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $8.00, for a total transaction of $64,000.00. Following the transaction, the director now owns 740,956 shares of the company’s stock, valued at $5,927,648. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.60% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Stock Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.